Viridian targets Horizon's Tepezza with chronic thyroid eye disease data, setting up the biotech for its second PhIII

Kyle LaHucik

Senior Reporter

Viridian Therapeutics said its IV-administered antibody led to clinical improvements in a small group of patients with the chronic form of thyroid eye disease, as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viridian targets Horizon's Tepezza with chronic thyroid eye disease data, setting up the biotech for its second PhIII

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

Breaking down silos with a new quantitative approach to drug development

Virid­i­an tar­gets Hori­zon's Te­pez­za with chron­ic thy­roid eye dis­ease da­ta, set­ting up the biotech for its sec­ond PhI­II

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Viridian targets Horizon's Tepezza with chronic thyroid eye disease data, setting up the biotech for its second PhIII